Mark Iwicki Purchases Shares of QTTB
Mark Iwicki acquired 9,810 shares of QTTB on June 12, 2026.
Key Points
- Mark Iwicki bought 9,810 shares of QTTB on June 12, 2026, with the stock trading at $12.75.
- QTTB's stock is currently trading near $12.75, with several insiders making similar purchases.
- Analysts from Mizuho and HC Wainwright & Co. have given QTTB a 'buy' rating recently.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
On June 12, 2026, Mark Iwicki bought 9,810 shares of QTTB. This insider purchase was not part of a pre-planned trading program. The stock was trading at $12.75 at the time of the transaction.
Insider Buying and Selling at Q32 Bio Inc.
Several insiders, including Mark Iwicki, Kathleen Laporte, David Grayzel, Arthur Tzianabos, Sven Ante Lundberg, and Diyong Xu, each purchased 9,810 shares of QTTB on June 12, 2026. These transactions were not pre-planned.
Other Institutional Activity in QTTB
Opaleye Management Inc. significantly increased its position by 1,042,865 shares, ending with 1,256,228 shares valued at approximately $8.06 million. OrbiMed Advisors LLC, Atlas Venture Life Science Advisors, LLC, and Carlyle Group Inc. maintained their holdings with no changes, holding 2,252,987 shares, 2,092,106 shares, and 1,102,741 shares, respectively. Acorn Capital Advisors, LLC, however, reduced its stake by 178,373 shares to 315,052 shares, valued at about $2.02 million.
Q32 Bio Inc. Stock Down 15.2%
Shares of QTTB are currently trading near $12.75. Although specific financial metrics such as market cap and P/E ratio are not available, the stock's activity reflects interest from both insiders and institutional investors.
Analysts Set New Price Targets
On May 22, 2026, Mizuho initiated coverage on QTTB with a 'buy' rating and a $14.00 price target. HC Wainwright & Co. reiterated its 'buy' rating on May 5, 2026, with a target of $13.00. The consensus among analysts suggests a positive outlook, with a mean target price reflecting potential upside.
Bottom Line
Mark Iwicki's recent purchase of QTTB shares highlights insider confidence in the company. The stock is drawing attention from both insiders and analysts, with several 'buy' ratings suggesting optimism. While 13F filings and insider transactions offer a glimpse into investor sentiment, they reflect past actions and do not necessarily indicate future performance.
Get Q32 Bio Inc. alerts
New 13F filings, insider trades, and analyst moves on $QTTB, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.